Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) after prior treatment (tx) with FUL in patients (pts) with advanced breast cancer (ABC): A real-world (RW) analysis.

被引：0
|
作者：
O'Shaughnessy, Joyce
Woeckel, Achim
Pistilli, Barbara
Hegg, Roberto
Vahdat, Linda T.
Vuina, Dragica
Asad, Zvk Parisa
Smith, Timothy W.
Kim, Julia
Krop, Ian
机构：
[1] Baylor Univ Med Ctr, Texas Oncol, US Oncol Network, Dallas, TX USA
[2] Univ Wurzburg, Wurzburg, Germany
[3] Inst Macerata, Macerata, Italy
[4] Univ Sao Paulo, Sao Paulo, SP, Brazil
[5] Dartmouth Canc Ctr, Lebanon, NH USA
[6] Novartis Oncol, Zagreb, Croatia
[7] Novartis Oncol, Basel, Switzerland
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Genesis Res, Hoboken, NY USA
[10] Dana Farber Canc Inst, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1055
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Investigating real-world treatment sequencing outcomes in advanced pancreatic cancer: A purple translational registry analysis.
    Santucci, Jordan
    Lee, Belinda
    Mendis, Shehara Ramyalini
    Thomson, Benjamin N.
    Michael, Michael
    Shapiro, Julia
    Wong, Rachel
    Clarke, Kate
    Pattison, Sharon Tracy
    Burge, Matthew E.
    Zielinski, Robert Richard
    Nikfarjam, Mehrdad
    Ananda, Sumitra
    Lipton, Lara Rachel
    Gibbs, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [32] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA
    Decker, Thomas
    Brucker, Cosima
    Engel, Anne
    Fasching, Peter A.
    Goehler, Thomas
    Jackisch, Christian
    Janssen, Jan
    Koehler, Andreas
    Luedtke-Heckenkamp, Kerstin
    Lueftner, Diana
    van Mackelenbergh, Marion
    Marme, Frederik
    Nusch, Arnd
    Rautenberg, Beate
    Reimer, Toralf
    Schmidt, Marcus
    Weide, Rudolf
    Wimberger, Pauline
    Roos, Christian
    Woeckel, Achim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [33] Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer
    Turner, Stuart
    Chia, Stephen
    Kanakamedala, Hemanth
    Hsu, Wei-Chun
    Park, Jinhee
    Chandiwana, David
    Ridolfi, Antonia
    Yu, Chu-Ling
    Zarate, Juan Pablo
    Rugo, Hope S.
    ONCOLOGIST, 2021, 26 (07): : E1133 - E1142
  • [34] Real-world (RW) multi-country study of BRCA1/2 testing in adult patients (pts) with HER2-advanced breast cancer (ABC)
    Lux, M. P.
    Niyazov, A.
    Lewis, K.
    Rider, A.
    Arondekar, B.
    Mahtani, R.
    ANNALS OF ONCOLOGY, 2020, 31 : S368 - S369
  • [35] Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA.
    Lueftner, Diana
    Brucker, Cosima
    Decker, Thomas
    Fasching, Peter A.
    Goehler, Thomas
    Jackisch, Christian
    Janssen, Jan
    Koehler, Andreas
    Luedtke-Heckenkamp, Kerstin
    Van Mackelenbergh, Marion
    Marme, Frederik
    Nusch, Arnd
    Rautenberg, Beate
    Reimer, Toralf
    Schmidt, Marcus
    Weide, Rudolf
    Wimberger, Pauline
    Nabieva, Naiba
    Roos, Christian
    Woeckel, Achim
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Real-world treatment patterns and outcomes in patients (pts) with advanced, ALK plus non-small cell lung cancer (NSCLC) in Europe
    Stoyanov, N.
    Anderson, D.
    Combest, A.
    Nguyen, B.
    Ognar, R.
    Reitsma, D.
    Capart, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S860 - S860
  • [37] Real-World US Treatment Patterns and Clinical Outcomes in Advanced NSCLC After Prior Platinum Chemotherapy and Immunotherapy
    Smith, T.
    Knoll, S.
    Martinalbo, J.
    Ye, F.
    Kolaei, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1001 - S1001
  • [38] Use of circulating tumor DNA (ctDNA) for early assessment of treatment response in patients with advanced colorectal cancer (aCRC): A real-world (RW) analysis.
    Kasi, Pashtoon Murtaza
    Weipert, Caroline
    Nguyen, Tim
    Liao, Jiemin
    Zhang, Nicole
    Forbes, Shaun
    Gordon, Sean
    Tan, Benjamin R.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 246 - 246
  • [39] Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
    Rosalba Torrisi
    Raffaella Palumbo
    Rita De Sanctis
    Patrizia Vici
    Giulia Valeria Bianchi
    Laura Cortesi
    Vita Leonardi
    Rossana Gueli
    Alessandra Fabi
    Maria Rosaria Valerio
    Anna Rita Gambaro
    Barbara Tagliaferri
    Laura Pizzuti
    Marina Elena Cazzaniga
    Armando Santoro
    Breast Cancer Research and Treatment, 2021, 190 : 103 - 109
  • [40] Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9)
    Torrisi, Rosalba
    Palumbo, Raffaella
    De Sanctis, Rita
    Vici, Patrizia
    Bianchi, Giulia Valeria
    Cortesi, Laura
    Leonardi, Vita
    Gueli, Rossana
    Fabi, Alessandra
    Valerio, Maria Rosaria
    Gambaro, Anna Rita
    Tagliaferri, Barbara
    Pizzuti, Laura
    Cazzaniga, Marina Elena
    Santoro, Armando
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 190 (01) : 103 - 109
12345